Explore
Validate
Learn
Western blot
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [10]
- Comments [0]
- Validations
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN180514 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-V-Erb-B2 erythroblastic Leukemia Viral Oncogene Homolog 2, Neuro/glioblastoma Derived Oncogene Homolog (Avian) (ERBB2) (C-Term), (pTyr1248) antibody
- Antibody type
- Monoclonal
- Antigen
- Tyrosine-phosphorylated synthetic peptide corresponding to the C-terminus of humanc-erbB-2 protein (P-Tyr1248). AA Sequence: 1242-1255 with pTyr1248 [Lys- TAENPE-pY-LGLDVPV]Remarks: Mol. Wt. of Antigen: 185 kDa.
- Description
- Purified
- Reactivity
- Human, Rat
- Host
- Mouse
- Epitope
- C-Term,pTyr1248
- Isotype
- IgG
- Antibody clone number
- PN2A
- Vial size
- 0.1 mg
- Storage
- Store the antibody at 2 - 8°C up to one month or in aliquots at -20°C for longer. Avoidrepeated freezing and thawing.Shelf life: one year from despatch.
Submitted references The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells.
Active signaling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ: clinicopathological correlates.
Multisite phosphotyping of the ErbB-2 oncoprotein in human breast cancer.
Association of ErbB2 Ser1113 phosphorylation with epidermal growth factor receptor co-expression and poor prognosis in human breast cancer.
High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo.
Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer.
c-erbB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells.
Active signaling by Neu in transgenic mice.
Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours.
Activation state-specific monoclonal antibody detects tyrosine phosphorylated p185neu/erbB-2 in a subset of human breast tumors overexpressing this receptor.
Xu W, Yuan X, Jung YJ, Yang Y, Basso A, Rosen N, Chung EJ, Trepel J, Neckers L
Cancer research 2003 Nov 15;63(22):7777-84
Cancer research 2003 Nov 15;63(22):7777-84
Active signaling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ: clinicopathological correlates.
DiGiovanna MP, Chu P, Davison TL, Howe CL, Carter D, Claus EB, Stern DF
Cancer research 2002 Nov 15;62(22):6667-73
Cancer research 2002 Nov 15;62(22):6667-73
Multisite phosphotyping of the ErbB-2 oncoprotein in human breast cancer.
Ouyang X, Gulliford T, Huang GC, Harper-Wynne C, Shousha S, Epstein RJ
Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology 2001 Mar;6(1):17-25
Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology 2001 Mar;6(1):17-25
Association of ErbB2 Ser1113 phosphorylation with epidermal growth factor receptor co-expression and poor prognosis in human breast cancer.
Ouyang X, Gulliford T, Zhang H, Smith G, Huang G, Epstein RJ
Molecular and cellular biochemistry 2001 Feb;218(1-2):47-54
Molecular and cellular biochemistry 2001 Feb;218(1-2):47-54
High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo.
Christensen JG, Schreck RE, Chan E, Wang X, Yang C, Liu L, Cui J, Sun L, Wei J, Cherrington JM, Mendel DB
Clinical cancer research : an official journal of the American Association for Cancer Research 2001 Dec;7(12):4230-8
Clinical cancer research : an official journal of the American Association for Cancer Research 2001 Dec;7(12):4230-8
Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer.
Thor AD, Liu S, Edgerton S, Moore D 2nd, Kasowitz KM, Benz CC, Stern DF, DiGiovanna MP
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000 Sep 15;18(18):3230-9
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000 Sep 15;18(18):3230-9
c-erbB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells.
Brandt BH, Roetger A, Dittmar T, Nikolai G, Seeling M, Merschjann A, Nofer JR, Dehmer-Möller G, Junker R, Assmann G, Zaenker KS
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 1999 Nov;13(14):1939-49
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 1999 Nov;13(14):1939-49
Active signaling by Neu in transgenic mice.
DiGiovanna MP, Lerman MA, Coffey RJ, Muller WJ, Cardiff RD, Stern DF
Oncogene 1998 Oct 8;17(14):1877-84
Oncogene 1998 Oct 8;17(14):1877-84
Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours.
DiGiovanna MP, Carter D, Flynn SD, Stern DF
British journal of cancer 1996 Sep;74(5):802-6
British journal of cancer 1996 Sep;74(5):802-6
Activation state-specific monoclonal antibody detects tyrosine phosphorylated p185neu/erbB-2 in a subset of human breast tumors overexpressing this receptor.
DiGiovanna MP, Stern DF
Cancer research 1995 May 1;55(9):1946-55
Cancer research 1995 May 1;55(9):1946-55
No comments: Submit comment
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- Image(s): Immunohistochemistry
